Advertisement

Drugs, Alcohol, and Pregnant Women: Anesthetic Implications for Mother and Newborn

  • Migdalia SaloumEmail author
  • Jonathan N. Epstein
Chapter

Abstract

The prevalence of substance abuse among young adults has increased markedly over the last 20 years. Since nearly 90% of drug-abusing women are of childbearing age, it is likely that the clinician will encounter pregnant women who abuse illicit drugs [1]. As many case reports confirm, life-threatening complications may result when the physiologic changes of pregnancy are combined with the adverse effects of drug abuse [2]. Anesthesiologists are likely to meet the drug-abusing parturient first in an acute setting either when labor analgesia is requested or in an emergency situation such as fetal distress, placental abruption, uterine rupture, or sudden onset of life-threatening maternal dysrhythmias. Risk factors suggesting drug abuse in pregnancy include lack of prenatal care, history of premature labor, and cigarette smoking [3]. The most common illicit substances encountered are alcohol, cocaine, amphetamines, opioids, marijuana, and tobacco.

Keywords

Prenatal Care Sudden Infant Death Syndrome Fetal Alcohol Spectrum Disorder Fetal Alcohol Spectrum Disorder Uterine Rupture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    National Survey on Drug Use and Health. Substance abuse during pregnancy: 2002 and 2003 update. www.oas.samhsa.gov/2k5/pregnancy/pregnancy.htm. Accessed 13 Sep 2010.
  2. 2.
    Samuels SI, Maze A, Albright G. Cardiac arrest during cesarean section in a chronic amphetamine abuser. Anesth Analg. 1979;58:528–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Floyd RL, Decoufle P, Hungerford DW. Alcohol use prior to pregnancy recognition. Am J Prev Med. 1999;17:101–7.PubMedCrossRefGoogle Scholar
  4. 4.
    State vs. Regina McKnight. 2003.Google Scholar
  5. 5.
    Commonwealth of Kentucky vs. Ina Cochran. case#2008-sc-000095. 2005.Google Scholar
  6. 6.
    American College of Obstetricians and Gynecologists. Committee opinion on obstetrics: Maternal and fetal medicine. Cocaine in pregnancy ACOG committee opinion No:114, Washington, DC. September 1992.Google Scholar
  7. 7.
    Kilmer G, Roberts H, Hughes E, Li Y, Valluru B, Fan A, et al. Surveillance of certain health behaviors and conditions among states and selected local areas – behavioral risk factor surveillance system, United States, 2006. MMWR Surveill Summ. 2008;57(7):1–188.PubMedGoogle Scholar
  8. 8.
    Kuczkowski KM. Anesthetic implications of drug abuse in pregnancy. J Clin Anesth. 2003;15:382–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen-Kerem R, Koren G. Antioxidants and fetal protection against ethanol teratogenicity I. review of the experimental data and implications to humans. Neurotoxicol Teratol. 2003;25:1–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Ornoy A, Ergaz Z. Alcohol abuse in pregnant women: effects on the fetus and newborn, mode of action and maternal treatment. Int J Environ Res Public Health. 2010;7:364–79.PubMedCrossRefGoogle Scholar
  11. 11.
    Keegan J, Parva M, Finnegan M, Gerson A, Belden M. Addiction in pregnancy. J Addict Dis. 2010;29:175–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Lemoine P, Harousseau H, Borteryu JP, Menuet JC. Children of alcoholic parents: abnormalities observed in 127 cases. Ouest Med. 1968;8:476–82.Google Scholar
  13. 13.
    Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet. 1973;2:999–1001.CrossRefGoogle Scholar
  14. 14.
    Hannigan JH, Armant DR. Alcohol in pregnancy and neonatal outcome. Semin Neonatol. 2000;5:243–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Floyd RL, Jack BW, Cefalo R, Atrash H, Mahoney J, Herron A. The clinical content of preconception care: alcohol, tobacco, and illicit drug exposures. Am J Obstet Gynecol. 2008;199:s333–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Kesmodel U, Wisborg K, Olsen SF, Henriksen TB, Secher NJ. Moderate alcohol intake in pregnancy and the risk of spontaneous abortion. Alcohol Alcohol. 2002;37:87–92.PubMedGoogle Scholar
  17. 17.
    Martinez-Frias ML, Bernejo E, Rodriguez-Pinilla E, Frias JL. Risk for congenital anomalies associated with different sporadic and daily doses of alcohol consumption during pregnancy: a case control study. Birth Defects Res A Clin Mol Teratol. 2004;70:194–200.PubMedCrossRefGoogle Scholar
  18. 18.
    Stoler JM, Holmes LB. Recognition of facial features of fetal alcohol syndrome in the newborn. Am J Med Genet. 2004;127C:21–4.PubMedCrossRefGoogle Scholar
  19. 19.
    May PA, Gossage JP. Estimating the prevalence of fetal alcohol syndrome. A summary. Alcohol Res Health. 2005;25:159–67.Google Scholar
  20. 20.
    Hoyme HE, May PA, Kalberg WO, Kodituwakku P, Gosssage JP, Trujillo PM, et al. A practical clinical approach to diagnosis of fetal alcohol spectrum disorders: clarification of the 1996 Institute of Medicine criteria. Pediatrics. 2005;115:39–47.PubMedCrossRefGoogle Scholar
  21. 21.
    Banakar MK, Kudlur NS, George S. Fetal alcohol spectrum disorder (FASD). Indian J Pediatr. 2009;76:1173–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Wagner CL, Katikaneni LD, Cox TH, et al. The impact of prenatal drug exposure on the neonate. Obstet Gynecol Clin North Am. 1998;25:169–94.PubMedCrossRefGoogle Scholar
  23. 23.
    Han YH. Why do chronic alcoholics require more anesthesia? Anesthesiology. 1969;30:2.CrossRefGoogle Scholar
  24. 24.
    Swerdlow BN, Holley FO, Maitre PO, et al. Chronic alcohol intake does not change thiopental anesthetic requirement, pharmacokinetics, or pharmacodynamics. Anesthesiology. 1990;72:455–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Chestnut DH, Polley LS, Tsen LC, Wong CA. Obstetric anesthesia principles and practice. 4th ed. Philadelphia, PA: Mosby Elsevier; 2009. p. 1134–7.Google Scholar
  26. 26.
    Russell M, Martier S, Sokol R, Mudar P, Jacobson S, Jacobson J. Detecting risk drinking during pregnancy: a comparison of four screening questionnaires. Am J Public Health. 1996;86:1435–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Burns E, Gray R, Smith LA. Brief screening questionnaires to identify problem drinking during pregnancy: a systematic review. Addiction. 2010;105:601–14.PubMedCrossRefGoogle Scholar
  28. 28.
    Gareri J, Klein J, Koren G. Drug of abuse testing in meconium. Clin Chim Acta. 2006;366:101–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Ostrea Jr EM, Hernandez JD, Bielawski DM, Kan JM, et al. Fatty acid ethyl esters in meconium: are they biomarkers of fetal alcohol exposure and effect? Alcohol Clin Exp Res. 2006;30(7):1152–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Burd L, Hofer R. Biomarkers for detection of prenatal alcohol exposure: a critical review of fatty acid ethyl esters in meconium. Birth Defects Res A Clin Mol Teratol. 2008;82(7):487–93.PubMedCrossRefGoogle Scholar
  31. 31.
    National Institute on Drug Abuse SAaMHSA: Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD: National Institute on Drug Abuse; 2009.Google Scholar
  32. 32.
    King JC. Substance abuse in pregnancy. Postgrad Med J. 1997;102:135–50.Google Scholar
  33. 33.
    McCalla S, Minkoff HL, Feldman J, et al. Predictors of cocaine use in pregnancy. Obstet Gynecol. 1992;79:641–4.PubMedGoogle Scholar
  34. 34.
    Birnbach DJ, Browne IM, Kim A, et al. Identification of polysubstace abuse in the parturient. Br J Anaesth. 2001;87:488–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Oyler J, Darwin WD, Preston KL, et al. Cocaine disposition in the meconium from newborns of cocaine abusing mothers and urine of adult drug users. J Anal Toxicol. 1996;20(6):453–562.PubMedGoogle Scholar
  36. 36.
    Plessinger MA, Woods JR. Maternal, placental and fetal pathophysiology of cocaine exposure during pregnancy. Clin Obstet Gynecol. 1993;36:267–78.PubMedCrossRefGoogle Scholar
  37. 37.
    Andres RL. Social and illicit drug use in pregnancy. Maternal fetal med: principles and practice. 5th ed. W.B. Saunders: Philadelphia, PA; 2004. p. 55–67.Google Scholar
  38. 38.
    Buehler BA. Cocaine how dangerous is it during pregnancy? Nebr Med J. 1995;80:116–7.PubMedGoogle Scholar
  39. 39.
    Moen MD, Caliendo MJ, Marshall W, et al. Hepatic rupture in pregnancy associated with cocaine use. Obstet Gynecol. 1993;82:687–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Chao CR. Cardiovascular effects of cocaine during pregnancy. Semin Perinatol. 1996;20:107–14.PubMedCrossRefGoogle Scholar
  41. 41.
    Moore TR, Sorg J, Miller L, et al. Hemodynamic effects of intravenous cocaine on the pregnant ewe and fetus. Am J Obstet Gynecol. 1986;155:883–8.PubMedGoogle Scholar
  42. 42.
    Schindler CW, Tella SR, Erzanki HK. Pharmacological mechanisms of cocaine’s cardiovascular effects. Drug Alcohol Depend. 1995;37:183–91.PubMedCrossRefGoogle Scholar
  43. 43.
    Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001;345:351–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Shanti CM, Lucas CE. Cocaine and the critical care challenge. Crit Care Med. 2003;31:1851–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Restrepo CS, Carrillo JA, Martínez S, Ojeda P, Rivera AL, Hatta A. pulmonary complications from cocaine and cocaine based substances: imaging maifestations. Radiographics. 2007;27(4):941–56.PubMedCrossRefGoogle Scholar
  46. 46.
    Kuczkowski KM, Birnbach DJ, van Zundert A. Drug Abuse in the Parturient. Semin Anesth Periop Med Pain. 2000;19:216–24.CrossRefGoogle Scholar
  47. 47.
    Kreek MJ. Cocaine, dopamine and the endogenous opioid system. J Addict Dis. 1996;15:73–96.PubMedCrossRefGoogle Scholar
  48. 48.
    Vertommen JD, Hughes SC, Rosen MA, et al. Hydralazine, does not restore uterine blood flow during cocaine-induced hypertension in the pregnant ewe. Anesthesiology. 1992;76:580–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Guidelines 2010 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S829–61.© 2010 American Heart Association, Inc.Google Scholar
  50. 50.
    Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;112:897–903.PubMedGoogle Scholar
  51. 51.
    Kain ZN, Mayes LC, Ferris CA, et al. Cocaine-abusing parturients undergoing cesarean section: a cohort study. Anesthesiology. 1996;85:1028–35.PubMedCrossRefGoogle Scholar
  52. 52.
    Spence MR, Williams R, DiGregorio GJ, et al. The relationship between recent cocaine use and pregnancy outcome. Obstet Gynecol. 1991;78:326–9.PubMedGoogle Scholar
  53. 53.
    Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104:1085–99.PubMedCrossRefGoogle Scholar
  54. 54.
    Good MM, Solt I, Acuna JG, Rotsmensch S, Kim MJ. Methamphetamine use during pregnancy. Obstet Gynecol. 2010;116(2):330–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Terplan M, Smith EJ, Kozloski MJ, Pollack HA. Methamphetamine use among pregnant women. Obstet Gynecol. 2009;113:1285–91.PubMedGoogle Scholar
  56. 56.
    Arria AM, Derauf C, Lagasse LL, Grant P, Shah R, Smith L, et al. Methamphetamine and other substance use during pregnancy. preliminary estimates from the infant development, environment, and lifestyle (IDEAL) study. Matern Child Health J. 2006;10:293–302.PubMedCrossRefGoogle Scholar
  57. 57.
    Gonzales R, Mooney L, Rawson AR. The methamphetamine problem in the united states. Annu Rev Public Health. 2010;31:385–98.PubMedCrossRefGoogle Scholar
  58. 58.
    Inoue H, Nakatome M, Terada M, Mizuno M, Ono R, Iino M, et al. Maternal methamphetamine administration during pregnancy influences on fetal rat heart development. Life Sci. 2004;74:1529–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Bateman DN, McElhatton PR, Dickinson D, Wren C, Matthews JN, O’Keffe M, et al. A case control study to examine the pharmacological factors underlying ventricular septal defects in the north of England. Eur J Clin Pharmacol. 2004;60:635–41.PubMedCrossRefGoogle Scholar
  60. 60.
    Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology. 2003;14:349–54.PubMedGoogle Scholar
  61. 61.
    Thomas DB. Cleft palate, mortality and morbidity of infants of substance abusing mothers. J Paediatr Child Health. 1995;31:457–60.PubMedCrossRefGoogle Scholar
  62. 62.
    Bays J. Fetal vascular disruption with prenatal exposure to cocaine or methamphetamine. Pediatrics. 1991;87:416–8.PubMedGoogle Scholar
  63. 63.
    Nora JJ, Vargo TA, Nora AH, Love KE, McNamara DG. Dexamphetamine: a possible environmental trigger in cardiovascular malformations. Lancet. 1970;1:1290–1.PubMedCrossRefGoogle Scholar
  64. 64.
    Little BB, Snell LM, Gilstrap 3rd LC. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol. 1988;72:541–4.PubMedGoogle Scholar
  65. 65.
    Milkovich L, Van der Berg BJ. effects of antenatal exposure to anorectic drugs. Am J Obstet Gynecol. 1977;129:637–42.PubMedGoogle Scholar
  66. 66.
    Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. J Pediatr. 1987;111:571–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Stewart JL, Meeker JE. Fetal and infant deaths associated with maternal methamphetamine abuse. J Anal Toxicol. 1997;21:515–7.PubMedGoogle Scholar
  68. 68.
    Michel R, Adams AP. Acute amphetamine abuse. Problems during general anesthesia for neurosurgery. Anaesthesia. 1979;34:1016–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Johnston RR, Way WL, Miller RD. Alteration of anesthetic requirement by amphetamine. Anesthesiology. 1972;36:357–63.PubMedCrossRefGoogle Scholar
  70. 70.
    Floyd RL, Jack BW, Cefalo R, Atrash H, Mahoney J, Herron A, et al. The clinical content of preconception care: alcohol, tobacco, and illicit drug exposures. Am J Obstet Gynecol. 2008;199:s333–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Brown HL, Britton KA, Mahaffey D, Brizendine E, Hiert AK, Turnquest MA. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol. 1998;179:459–63.PubMedCrossRefGoogle Scholar
  72. 72.
    Minozzi S, Amato L, Vecchi S, Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane database Syst Rev. 2008;CD006318.Google Scholar
  73. 73.
    Creasy RK, Resnik R, Iams JD. Creasy and Resnik’s maternal-fetal medicine: principles and practice. Philadelphia, PA: Saunders/Elsevier; 2009.Google Scholar
  74. 74.
    Lim S, Prasad MR, Samuels P, Gardner DK, Cordero L. High dose methadone in pregnant women and it’s effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol. 2009;200:70el–5.CrossRefGoogle Scholar
  75. 75.
    Rettig R. Federal regulation of methadone: table of contents and executive summary. Washington, DC: National Academy Press; 1995.Google Scholar
  76. 76.
    Rayburn W, Bogenschutz MP. Pharmacotherapy for pregnant women with addiction. Am J Obstet Gynecol. 2004;191:1885–97.PubMedCrossRefGoogle Scholar
  77. 77.
    Briggs G, Freeman R, Yaffe J. Drugs in pregnancy and lactation. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.Google Scholar
  78. 78.
    Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin N Am. 1998;25:139–51.CrossRefGoogle Scholar
  79. 79.
    Fajemirokun-Odudeyi O, Sinha C, Tutty S, Pairaudeau P, Armstrong D, Phillips T, et al. Pregnancy outcomes in women who use opiates. Eur J Obstet Gynecol Reprod Biol. 2006;126(2):170–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol. 2004;44(4):301–6.CrossRefGoogle Scholar
  81. 81.
    Gold MS, Pottash AL, Sweeney DR, Kleber HD. Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. JAMA. 1980;243:343–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Kuczkowski KM, Birnbach DDJ. The HIV infected parturient: is neuraxial anesthesia contraindicated? Curr Anesthesiol Rep. 2000;2:118–21.Google Scholar
  83. 83.
    Ashton CH. Biomedical benefits of cannnabinoids. Addict Biol. 1999;4:111–26.PubMedCrossRefGoogle Scholar
  84. 84.
    Shiono PH, Klebanoff MA, Nugent RP, Cotch MF, Wilkins DG, Rollins DE, et al. The impact of cocaine and marijuana use on low birth weight and preterm birth: a multicenter study. Am J Obstet Gynecol. 1995;172:19–27.PubMedCrossRefGoogle Scholar
  85. 85.
    Van Gelder M, Reefhuis J, Caton A, Werler M, Druschel C, et al. Characteristics of pregnant illicit drug users and associations between cannabis use an perinatal outcome in a population based study. Drug Alcohol Depend. 2010;109:243–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Musty RE, Reggio P, Consroe P. A review of recent advances in cannaboid research and the 1994 international symposium on cannabis and the cnnaboids. Life Sci. 1995;56:1933–40.PubMedCrossRefGoogle Scholar
  87. 87.
    National institute on drug abuse (NIDA) research report series: Marijuana abuse. July 2005. NIH publication number 05–3859.Google Scholar
  88. 88.
    Smith CG, Asch RH. Drug abuse and reproduction. Fertil Steril. 1987;48:355–73.PubMedGoogle Scholar
  89. 89.
    Mallat A, Roberson J, Broch-Utne JG. Preoperative marijuana inhalation – an airway concern. Can J Anaesth. 1996;43:691–3.PubMedCrossRefGoogle Scholar
  90. 90.
    IARC (International agency for research on cancer) working group on the evaluation of carcinogenic risks to humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1–1438.Google Scholar
  91. 91.
    Goodwin RD, Keyes K, Simuro N. Mental disorders and nicotine dependence among pregnant women in the united states. Obstet Gynecol. 2007;109:875–83.PubMedCrossRefGoogle Scholar
  92. 92.
    Kandel DB, Griesler PC, Schaffran C. Educational attainment and smoking among women: risk factors and consequences for offspring. Drug Alcohol Depend. 2009;104 Suppl 1:S24–33.PubMedCrossRefGoogle Scholar
  93. 93.
    Thielen A, Klus H, Muller L. Tobacco smoke: unraveling a controversial subject. Exp Toxicol Pathol. 2008;60:141–56.PubMedCrossRefGoogle Scholar
  94. 94.
    Andres RL, Day MC. Perinatal complications associated with maternal tobacco use. Semin Neonatol. 2000;5:231–41.PubMedCrossRefGoogle Scholar
  95. 95.
    Einarson A, Riordan S. Smoking in pregnancy and lactation: a review of risks and cessation strategies. Eur J Clin Pharmacol. 2009;65:325–30.PubMedCrossRefGoogle Scholar
  96. 96.
    MacDorman MF, Cnattingius S, Hoffman HJ, Kramer MS, Haglund B. Sudden infant death syndrome and smoking in the United states and Sweden. Am J Epidemiol. 1997;146:249–57.PubMedCrossRefGoogle Scholar
  97. 97.
    Simmons LE, Rubens CE, Darmstadt GL, et al. Preventing preterm birth and neonatal mortality: exploring the epidemiology, causes and interventions. Semon Perinatol. 2010;34(6):408–15.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of AnesthesiologySt. Luke’s Roosevelt HospitalNew YorkUSA
  2. 2.College of Physicians and SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations